A Phase 2 Trial to Evaluate the Safety and Efficacy of Domvanalimab (AB154) and Zimberelimab (AB122) -Based Treatment Combinations in Patients with Advanced Upper Gastrointestinal Tract Malignancies
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Arcus Biosciences
Start Date
November 9, 2022
End Date
November 8, 2027
Administered By
Duke Cancer Institute
Awarded By
Arcus Biosciences
Start Date
November 9, 2022
End Date
November 8, 2027